LEADER 00932nam0-2200289---450- 001 990009353560403321 005 20120110154125.0 010 $a978-92-79-07277-2 035 $a000935356 035 $aFED01000935356 035 $a(Aleph)000935356FED01 035 $a000935356 100 $a20110505d2008----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $a--------001yy 200 1 $a<>futuro sostenibile nelle nostre mani$euna guida strategica dell'UE in materia di sviluppo sostenibile 210 $aLussemburgo$cUfficio delle pubblicazioni ufficiali delle Comunità europee$d2008 215 $a79 p.$cill.$d21 cm 710 02$aCommissione europea.$bSegretariato generale$0510957 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009353560403321 952 $a62 1410.CE 19$b10611$fDAGEA 959 $aDAGEA 996 $aFuturo sostenibile nelle nostre mani$9767852 997 $aUNINA LEADER 03205oam 2200985zu 450 001 9910703085703321 005 20230902162045.0 010 $a0-585-21143-4 035 $a(CKB)111000211325648 035 $a(SSID)ssj0000238714 035 $a(PQKBManifestationID)12076199 035 $a(PQKBTitleCode)TC0000238714 035 $a(PQKBWorkID)10234073 035 $a(PQKB)10414703 035 $a(OCoLC)746570155 035 $a(OCoLC)746498364 035 $a(EXLCZ)99111000211325648 100 $a20160829d2000 uy 101 0 $aeng 135 $aurmn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aRitalin : theory and practice 210 31$a[Place of publication not identified]$cM A Liebert Publishers$d2000 215 $a1 online resource (2 unnumbered pages) $cillustrations 225 1 $aDatos ra?pidos 225 1 $aPreguntas y respuestas 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-913113-82-4 410 0$aDatos ra?pidos (National Drug Intelligence Center (U.S.)) 410 0$aPreguntas y respuestas (National Drug Intelligence Center (U.S.)) 606 $aMethylphenidate$xChemotherapy 606 $aAttention-deficit hyperactivity disorder 606 $aPharmacology 606 $aMethylphenidate 606 $aDrug Therapy 606 $aAttention Deficit Disorder with Hyperactivity 606 $aPiperidines 606 $aBiological Science Disciplines 606 $aAttention Deficit and Disruptive Behavior Disorders 606 $aPhenylacetates 606 $aTherapeutics 606 $aHeterocyclic Compounds, 1-Ring 606 $aNeurodevelopmental Disorders 606 $aAcids, Carbocyclic 606 $aNatural Science Disciplines 606 $aMental Disorders 606 $aCarboxylic Acids 606 $aHeterocyclic Compounds 606 $aOrganic Chemicals 606 $aPediatrics$2HILCC 606 $aMedicine$2HILCC 606 $aHealth & Biological Sciences$2HILCC 615 0$aMethylphenidate$xChemotherapy. 615 0$aAttention-deficit hyperactivity disorder. 615 2$aPharmacology. 615 2$aMethylphenidate. 615 2$aDrug Therapy. 615 2$aAttention Deficit Disorder with Hyperactivity. 615 2$aPiperidines. 615 2$aBiological Science Disciplines. 615 2$aAttention Deficit and Disruptive Behavior Disorders. 615 2$aPhenylacetates. 615 2$aTherapeutics. 615 2$aHeterocyclic Compounds, 1-Ring. 615 2$aNeurodevelopmental Disorders. 615 2$aAcids, Carbocyclic. 615 2$aNatural Science Disciplines. 615 2$aMental Disorders. 615 2$aCarboxylic Acids. 615 2$aHeterocyclic Compounds. 615 2$aOrganic Chemicals. 615 7$aPediatrics 615 7$aMedicine 615 7$aHealth & Biological Sciences 676 $a618.92/8589061 702 $aOsman$b Betty B. 702 $aGreenhill$b Laurence L. 712 02$aNational Drug Intelligence Center (U.S.) 801 0$bPQKB 906 $aBOOK 912 $a9910703085703321 996 $aRitalin : theory and practice$93135036 997 $aUNINA